AACR continues to reflect the pace of innovation in cancer research. AntibodySystem remains focused on expanding target coverage and improving reagent performance to support emerging areas including bispecific ADCs, multi-target strategies, and combination immunotherapies. We thank the researchers and partners who met with us during AACR 2026. Your feedback directly informs how we refine our products and support evolving research needs. We look forward to continued collaboration with the global research community.

In March 2026, AntibodySystem products continued to empower cutting-edge multidisciplinary research worldwide. Related findings were published in journals such as Nature Sensors, Phytomedicine, Alzheimer’s Research & Therapy, Virology, and ACS Nano. These studies span critical fields including early cancer diagnostics, bone metabolic diseases, renal fibrosis, neuroimaging, viral vaccines, and tumor immunotherapy, continuously driving innovation at the frontier of science and clinical translation.

In March 2026, Phytomedicine published a study titled "Asiaticoside attenuates renal fibrosis by targeting STAT3 to restore Th17/Treg homeostasis." The study reveals that asiaticoside (AS), a bioactive triterpenoid derived from Centella asiatica, exerts therapeutic effects through a previously unrecognized mechanism: it directly binds to STAT3 and induces its structural destabilization, leading to protein clearance.

March 2026. Kent, England. A cluster of invasive meningococcal disease cases, some fatal. Standard contact tracing soon revealed transmission links reaching into France. Nothing unusual there—until investigators noticed what several cases had in common: they had shared e-cigarettes at social gatherings.

In late February 2026, highly pathogenic avian influenza (H5N1) was detected for the first time in northern elephant seals at Año Nuevo State Park, California. By mid-March, multiple seal pups had died, with infected individuals exhibiting neurological symptoms such as tremors, seizures, and convulsions. Preliminary analyses suggest that the virus carries mutations associated with enhanced adaptation to mammalian hosts.

In February 2026, AntibodySystem products powered multidisciplinary research worldwide. Molecular Cancer revealed how Fusobacterium nucleatum manipulates host autophagy for immune evasion in nasopharyngeal carcinoma. Advanced Materials presented a circular RNA strategy to prevent vascular graft restenosis. Advanced Science showed indole-3-propionic acid improves bronchopulmonary dysplasia via autophagic flux regulation. Neoplasia uncovered the "energy symbiosis" between bladder cancer cells and adipocytes via fatty acids. Studies on Lassa virus drug repurposing, VDAC1-mtDNA in disc degeneration, and costunolide targeting HSP90 for colitis further advanced antiviral and degenerative disease research. AntibodySystem will continue empowering global researchers to expand the frontiers of life sciences and translational medicine.

Recent reports of Nipah virus (NiV) infections in India have once again drawn global attention to this highly lethal zoonotic pathogen. Despite its relatively low incidence, NiV is associated with case fatality rates of up to 75%, strong neurotropism, and the absence of licensed vaccines or specific antiviral therapies. As a result, Nipah virus remains a WHO priority pathogen, requiring sustained efforts in fundamental virology, immunology, and diagnostic development.

On World Leprosy Day, focusing not only on the disease itself but also on scientific research and technological advances is a vital force in driving the eventual elimination of leprosy. AntibodySystem remains committed to supporting global researchers in the field of leprosy and related immune diseases with high-quality products.

January 13th, 2026, a study published in Cell Stem Cell has drawn significant attention from the reproductive medicine and stem cell research communities. In the article entitled “Development of human induced pluripotent stem cell-derived ovarian support cells as a clinical-grade product for in vitro fertilization,” researchers from Gameto report the development of ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs) and their translation into a clinical-grade product for assisted reproduction.

In December 2025, multiple AntibodySystem products were cited in high-impact international journals, including Nature Communications and Advanced Science. These studies span cutting-edge research areas such as the pathogenicity and immune evasion of SARS-CoV-2 JN.1-derived variants, anti-tumor mechanisms of marine terpenoids targeting UBE2C, development of influenza/COVID-19 hybrid vaccines, regulation of erythropoiesis, and precision vaccine design for osteoporosis.

Recently, multiple regions in Japan have reported a sustained increase in syphilis cases, with annual confirmed infections exceeding 13,000 for four consecutive years. Epidemiological data indicate a clear shift toward younger populations, alongside a notable rise in cases among women. Once regarded as a “controllable and curable” sexually transmitted infection, syphilis is re-emerging in a more insidious and complex form, underscoring the need to move beyond textbook-level understanding of this disease.

A recent study published in Nature, entitled “Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation,” reports a case of long-term HIV-1 remission in a patient who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a donor carrying a heterozygous CCR5Δ32 mutation.